ORLANDO, Fla. — Rusfertide, a weekly self-injected peptide, maintained control of hematocrit levels and reductions in ...
Rusfertide maintained hematocrit control below 45% and reduced phlebotomy eligibility in PV patients through 52 weeks in the VERIFY study. Patients switching from placebo to rusfertide showed rapid ...
NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass., December 06, 2025--Protagonist Therapeutics, Inc. ("Protagonist") (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from ...
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety Signals These Data ...
Patients with polycythemia vera (PV) taking the investigational therapy rusfertide were able to largely maintain hematocrit control and avoid the need for phlebotomy over 52 weeks, according to ...
Every year, millions of newborns — especially those born premature, underweight or sick — are at risk of neonatal ...
Beyond blood cancers, GT Biopharma is developing GTB-5550, which targets B7H3, a protein commonly found across various solid tumor types including breast, lung, ovarian, pancreatic, bladder, and ...
Curating evidence-based lifestyle recommendations is key to achieving ideal cardiometabolic health in patients with obesity, as there is no “one-size-fits-all,” according to a presentation.At World ...
Tourniquets are used in knee arthroplasty surgeries for a bloodless field and effective bone-cement integration. However, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback